Readmission for heart failure remains a major focus of policymakers, clinicians, and patients. Despite meeting key national performance measures and frequent use of evidence-based therapies, rates of 30-day post-discharge rehospitalization may be as high as 25%. Digoxin and mineralocorticoid antagonists are known to reduce admissions for heart failure, but are significantly underused in current clinical practice despite their proven benefits.
- Acute heart failure
- Mineralocorticoid receptor antagonists
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine